Free PSA Test Awarded US Patent

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based company Wallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), have received a US patent for two methods of assaying free PSA (prostate-specific antigen).

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based companyWallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), havereceived a US patent for two methods of assaying free PSA (prostate-specificantigen).

The patent was issued to two inventors, Dr. Ulf-Hakan Stenman,of Helsinki University Central Hospital, and Dr. Hans Lilja, ofLund University.

The inventors gave exclusive rights to Wallac, which subsequentlygranted a sublicense to Abbott. The patent covers immmunoassaysfor free PSA and the use of the ratio of free-to-total PSA tobetter distinguish between prostate cancer and benign prostatichyperplasia (BPH).

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Related Content